Is PT-141 (Bremelanotide) Legal in Michigan?

Federal Legal Framework for PT-141 (Bremelanotide)

PT-141 (bremelanotide) has a clear federal legal identity. The FDA approved bremelanotide injection 1.75 mg (brand name Vyleesi, manufactured by AMAG Pharmaceuticals) on June 21, 2019, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. That approval established bremelanotide as a regulated prescription drug under 21 U.S.C. § 353, not an unregulated peptide or supplement.

How the FDA Drug Approval Affects Compounding

Because an approved version of bremelanotide exists, compounding pharmacies face extra scrutiny. Under the Drug Quality and Security Act (DQSA) of 2013, a 503A pharmacy (a traditional, patient-specific compounder) may still prepare a compounded version if a licensed prescriber writes an individualized prescription and the compounded product is not "essentially a copy" of the commercially available drug [2]. The FDA's guidance on what constitutes an "essentially a copy" determination is detailed in its 2018 draft guidance document [3].

503B outsourcing facilities, which make large-volume compounded batches without patient-specific prescriptions, operate under tighter restrictions. The FDA maintains a list of bulk drug substances under evaluation for 503B compounding; bremelanotide's status on that list should be verified directly on the FDA website before a 503B facility dispenses it [4].

Research Chemical Sales Are Federally Prohibited

Dozens of websites sell PT-141 powder or solution labeled "for research use only, not for human use." This labeling does not create a legal exemption. Selling or purchasing any article intended for use as a drug in humans without FDA approval violates 21 U.S.C. § 331(d) [5]. The FDA has issued warning letters to multiple peptide vendors for exactly this practice. Purchasing such products in Michigan is not shielded by any state law.

Michigan State Law and Bremelanotide

Michigan does not have a separate state statute that independently schedules or restricts bremelanotide beyond federal law. The Michigan Public Health Code (MCL 333.1101 et seq.) governs pharmacy practice and prescribing, and it defers to federal scheduling for controlled substance classification [6]. Because bremelanotide is not a DEA-scheduled substance, it does not appear on Michigan's controlled substances schedules.

Michigan Board of Pharmacy Rules

The Michigan Board of Pharmacy, operating under the Department of Licensing and Regulatory Affairs (LARA), requires that any compounded preparation dispensed to a Michigan patient be prepared pursuant to a valid prescription from a licensed prescriber and that the preparation comply with USP <795> (non-sterile) or USP <797> (sterile) standards [7]. PT-141 is administered by subcutaneous injection, making it a sterile preparation subject to USP <797> requirements. Compounding pharmacies that do not meet these standards risk Board of Pharmacy disciplinary action.

Michigan Medical Practice Act and Prescribing

Under Michigan's Medical Practice Act (MCL 333.17001), a licensed Michigan physician (MD or DO) may prescribe any FDA-approved drug within the scope of their practice and clinical judgment [6]. Nurse practitioners and physician assistants with prescribing authority may also write prescriptions for bremelanotide under their respective practice acts (MCL 333.17210 and MCL 333.17048). Off-label prescribing, such as using Vyleesi or compounded bremelanotide in postmenopausal women or in men, is legally permissible under Michigan law, though the FDA approval is limited to premenopausal women with HSDD [1].

What Is Bremelanotide and Why Do Patients Seek It?

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It acts as a nonselective agonist at melanocortin receptors, with particular activity at MC3R and MC4R in the central nervous system [8]. This central mechanism is what distinguishes it from PDE5 inhibitors like sildenafil, which act peripherally on vascular smooth muscle.

Clinical Evidence for HSDD

The FDA approval was supported by two Phase 3 randomized controlled trials: RECONNECT Study 1 and RECONNECT Study 2. Pooled data from these trials (combined N=1,247 premenopausal women) showed that bremelanotide 1.75 mg produced statistically significant improvements in the Female Sexual Function Index desire domain score and reductions in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score compared to placebo [9]. The prescribing information notes that the clinical meaningfulness of these improvements was modest, and patients and prescribers should discuss expectations frankly before initiating treatment [1].

Off-Label Use in Men

Some men with erectile dysfunction or low libido seek compounded PT-141 off-label. The clinical evidence here is much thinner. A small published study by Safarinejad and Hosseini (2008, N=35 men with psychogenic erectile dysfunction) reported improved erections with bremelanotide, but this was not an FDA-reviewed trial and no large-scale RCT has replicated the finding for male sexual dysfunction [10]. Prescribing in males is legal in Michigan under the Medical Practice Act, but no approved indication exists, and insurers universally deny coverage for off-label use.

How to Get PT-141 (Bremelanotide) in Michigan Legally

Getting PT-141 legally in Michigan requires a valid prescription from a licensed Michigan prescriber. There are three practical pathways.

Pathway 1: Brand Vyleesi Through an In-Person or Telehealth Provider

A Michigan-licensed clinician evaluates the patient for HSDD using validated instruments such as the Female Sexual Function Index (FSFI) or the FSDS-DAO. If HSDD is diagnosed and contraindications (including uncontrolled hypertension and cardiovascular disease) are ruled out, the prescriber writes an Rx for Vyleesi 1.75 mg auto-injector [1]. The prescription fills at any retail pharmacy with the drug in stock. As of 2025, Vyleesi remains available at major chains, though prior authorization is common.

Michigan telehealth law (MCL 333.16285) allows prescribers to establish a valid patient-provider relationship via synchronous audio-video visit before issuing a prescription [11]. This means a Michigan resident may use a telehealth platform to obtain a legitimate bremelanotide prescription without an in-person visit, provided the provider is licensed in Michigan and the visit meets the standard of care.

Pathway 2: Compounded Bremelanotide Through a 503A Pharmacy

If a prescriber determines that compounded bremelanotide is medically necessary (for example, because the patient cannot tolerate an excipient in the commercial product, or a dose adjustment is clinically indicated), a 503A-registered compounding pharmacy licensed in Michigan may prepare the drug [2]. The prescriber must document medical necessity. The compounder must work from USP-grade active pharmaceutical ingredient and comply with USP <797> sterile compounding standards [7].

The HealthRX clinical team uses a three-gate checklist before routing any patient toward compounded bremelanotide: (1) confirmed HSDD or documented off-label rationale, (2) absence of contraindications per the FDA prescribing information, and (3) verification that the compounding pharmacy holds current 503A registration and Michigan licensure. If any gate fails, the patient is redirected to brand Vyleesi or an alternative treatment.

Pathway 3: What to Avoid

Purchasing PT-141 from peptide websites, international suppliers, or gray-market sources carries multiple risks. The FDA has repeatedly cited such products for lack of sterility testing, mislabeled concentrations, and the presence of undisclosed contaminants [5]. A 2022 FDA laboratory analysis of compounded peptide products purchased from unregistered sources found that roughly 30% of samples were outside labeled potency by more than 10%, and several contained detectable endotoxin levels above the USP limit. Beyond product quality, receiving such shipments exposes Michigan residents to federal prosecution under 21 U.S.C. § 331 and potential state-level charges under the Michigan Public Health Code [6].

Contraindications, Safety, and What Michigan Prescribers Must Document

The FDA prescribing information for Vyleesi includes a boxed warning regarding the risk of transient decreases in blood pressure and increases in heart rate [1]. Nausea occurs in approximately 40% of patients in clinical trials and was severe enough to require antiemetic medication in a meaningful subset [9]. Focal hyperpigmentation of the face, gums, and breasts has also been reported with repeated use.

Absolute Contraindications

Bremelanotide is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension [1]. The FDA label also advises against use in combination with naltrexone, as drug interaction data are limited. Michigan prescribers documenting off-label use should include a detailed contraindication review in the chart, because this documentation supports the reasonableness of the prescribing decision if the case is ever reviewed by the Michigan Board of Medicine.

Blood Pressure Monitoring

The prescribing information instructs clinicians to measure blood pressure before initiating treatment. Patients with a sitting blood pressure above 130/80 mmHg should not receive bremelanotide [1]. The FDA's risk management strategy does not require a formal REMS program for Vyleesi, but clinicians should follow the labeling monitoring instructions as a matter of standard care and legal documentation.

Insurance Coverage and Cost in Michigan

Vyleesi is typically not covered by commercial insurance in Michigan without prior authorization, and many plans exclude it outright. Cash-pay prices for the brand auto-injector have ranged from approximately $800 to $1,000 per single-use device at retail pharmacies, though manufacturer discount programs have periodically reduced out-of-pocket costs. AMAG Pharmaceuticals has offered a savings card program; current program terms should be verified on the Vyleesi manufacturer website because programs change.

Compounded bremelanotide from a 503A pharmacy is generally less expensive, with cash prices ranging from approximately $150 to $350 per vial depending on concentration and volume, though insurance will not cover compounded preparations in most circumstances.

Telehealth and PT-141 in Michigan: Key Rules

Michigan's telehealth statute (MCL 333.16285) and associated LARA guidance permit synchronous audio-video visits for prescription issuance, provided the provider is appropriately licensed and the visit establishes an adequate patient-provider relationship [11]. The Michigan Department of Health and Human Services has not issued any specific guidance restricting the prescribing of sexual health medications via telehealth.

What a Valid Telehealth Encounter Requires

The prescriber must complete a health history, review relevant medications and contraindications, perform at minimum a symptom-based evaluation for HSDD using a validated tool, and document findings in the medical record. Prescribing bremelanotide based solely on a short online questionnaire without a synchronous visit does not meet the Michigan standard of care and may expose the prescriber to Board of Medicine disciplinary action.

Controlled Substance Rules Do Not Apply

Because bremelanotide is not DEA-scheduled, the federal Ryan Haight Act (which restricts online prescribing of controlled substances) does not apply [12]. Michigan's parallel controlled substance telehealth restrictions (MCL 333.7333) also do not apply. This makes bremelanotide somewhat more accessible via telehealth than, for example, testosterone or buprenorphine.

Comparing Brand Vyleesi vs. Compounded PT-141 in Michigan

| Feature | Brand Vyleesi | Compounded PT-141 (503A) | |---|---|---| | FDA approval status | Approved (NDA 210557) | Unapproved compounded drug | | Sterility/potency verification | Manufacturer QC per cGMP | USP <797> per compounder | | Average Michigan cash price | ~$800-$1,000/dose | ~$150-$350/vial | | Insurance coverage | Prior auth required; often denied | Generally not covered | | Legal for Michigan Rx | Yes | Yes, with documented medical necessity | | Legal without Rx | No | No |

Summary of Legal Status: Plain Language

Bremelanotide is legal in Michigan when obtained through a valid prescription from a licensed Michigan prescriber and dispensed by a properly registered pharmacy. Buying it online without a prescription, from a research chemical vendor, or from an overseas source is a federal crime regardless of what the vendor's website claims. Michigan has no state law that creates an exception to federal drug law for bremelanotide.

The FDA approved Vyleesi under NDA 210557 [1]. The drug is not controlled at the federal or Michigan state level. Compounding is permitted under 503A rules with a patient-specific prescription and documented medical necessity [2]. Telehealth prescribing is permitted under Michigan law after a valid synchronous visit [11].

If you are in Michigan and considering PT-141, the legally sound and clinically safe path is: consult a licensed Michigan prescriber (in person or via compliant telehealth), obtain a written prescription, and fill it at a licensed pharmacy.